(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2022 (19.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/099357 A1

(51) International Patent Classification:
*C07D 417/14* (2006.01) *A61K 31/506* (2006.01)
*A61P 35/00* (2006.01)

(21) International Application Number:
PCT/AU2021/051325

(22) International Filing Date:
10 November 2021 (10.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202011249267.6 10 November 2020 (10.11.2020) CN

(71) Applicant *(for all designated States except CN)*: **AUCENTRA THERAPEUTICS PTY LTD** [AU/AU]; c/-Bentleys, Level 5, 63 Pirie Street, Adelaide, South Australia 5000 (AU).

(71) Applicants *(for CN only)*: **CHANGZHOU QIANHONG BIO-PHARMA CO., LTD.** [CN/CN]; 518 Yunhe Road, Xinbei District, Changzhou, Jiangsu 213125 (CN). **CHANGZHOU LE SUN PHARMACEUTICALS LIMITED** [CN/CN]; 518 Yunhe Road, Xinbei District, Changzhou, Jiangsu 213125 (CN).

(72) Inventors: **WANG, Shudong**; 43/7 Liberman Close, Adelaide, South Australia 5000 (AU). **WANG, Hui**; No. 518 Yunhe Road, Xinbei District, Changzhou, Jiangsu (CN). **LV, Jinchen**; No. 518 Yunhe Road, Xinbei District, Changzhou, Jiangsu (CN). **LIU, Jun**; No. 518 Yunhe Road, Xinbei District, Changzhou, Jiangsu (CN).

(74) Agent: **MADDERNS PATENT & TRADE MARK ATTORNEYS**; Level 4, 19 Gouger Street, Adelaide, South Australia 5000 (AU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report (Art. 21(3))*

WO 2022/099357 A1

(54) Title: SUCCINATE AND CRYSTAL FORM THEREOF AS THERAPEUTICS

(57) Abstract: Disclosed are salts of N-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl) methyl) pyridin-2-yl) amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine and polymorphs thereof, which are inhibitors of protein kinases, in particular cyclin-dependent kinase 4/6 (CDK4/6), and can be used to treat proliferative disorders, such as cancer, and other diseases related to protein kinase/CDK activity.